Since IL-1β, an NLRPP3 inflammasome downstream cytokine, promotes synovial inflammation in RA patients, the IL-1β receptor antagonist anakinra has been approved for active RA patients unresponsive to csDMARDs [143]. The gene discussed is IL1B; the disease is rheumatoid arthritis.